Palatin Technologies Inc To Host Key Opinion Leader Webinar Transcript
Good morning, and welcome to the Palatin Technologies KOL webinar on dry eye disease. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Palatin website following the conclusion of the event.
I'd now like to turn the call over to your host, Carl Spana, Chief Executive Officer of Palatin Technologies. Please go ahead, Carl.
Thank you, Sara. Good morning, and welcome, everyone, to the Palatin Dry Eye Disease webinar.
We've designed a very nice seminar today. We have Dr. Eric D. Donnenfeld, who will start with covering what dry disease is, how he manages it, current treatments for dry eye disease and the unmet medical need, and some of the recently approved treatments. We'll follow it up with Dr. Michael Raizman, who will cover treatments in development and then we will focus on PL9643, Palatin's melanocortin agonist, which is in Phase III development as a treating -- for treating dry eye disease, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |